Endo Pharmaceuticals to Announce First Quarter 2010 Financial Results on April 30, 2010
CHADDS FORD, Pa., April 16 /PRNewswire-FirstCall/ — Endo Pharmaceuticals (Nasdaq: ENDP) will announce its first quarter 2010 financial results on April 30, 2010 and will host a conference call and webcast at 10:00 a.m. ET that day to discuss these results.
David P. Holveck, president and chief executive officer, Alan Levin, chief financial officer and Blaine Davis, vice president, corporate affairs will host the call. In addition, Ivan Gergel, M.D., executive vice president of research and development will be available during the question and answer period.
Investors and other interested parties may call 866-314-4865 (domestic) or 617-213-8050 (international) and enter passcode 89231778. Please dial in 10 minutes prior to the scheduled start time.
A replay of the call will be available from April 30 at 2:30 p.m. ET until 12:00 a.m. ET on May 7 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode 95608100.
A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on May 7. The replay can be accessed by clicking on “Events” in the Investor Relations section of the website.
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERMÃ‚®, a topical patch to relieve the pain of postherpetic neuralgia; PercocetÃ‚® and PercodanÃ‚® tablets for the relief of moderate-to-moderately severe pain; FROVAÃ‚® tablets for the acute treatment of migraine attacks with or without aura in adults; OPANAÃ‚® tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANAÃ‚® ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; VoltarenÃ‚® Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTASÃ‚® for the palliative treatment of advanced prostate cancer; SUPPRELINÃ‚® LA for the treatment of early onset puberty in children; and VALSTAR(TM) for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.
SOURCE Endo Pharmaceuticals